390 related articles for article (PubMed ID: 33246141)
1. "A LEAP 2 conclusions? Targeting the ghrelin system to treat obesity and diabetes".
Gupta D; Ogden SB; Shankar K; Varshney S; Zigman JM
Mol Metab; 2021 Apr; 46():101128. PubMed ID: 33246141
[TBL] [Abstract][Full Text] [Related]
2. Ghrelin Signaling: GOAT and GHS-R1a Take a LEAP in Complexity.
Abizaid A; Hougland JL
Trends Endocrinol Metab; 2020 Feb; 31(2):107-117. PubMed ID: 31636018
[TBL] [Abstract][Full Text] [Related]
3. Intestinal expression profiles and hepatic expression of LEAP2, ghrelin and their common receptor, GHSR, in humans.
Englund A; Gilliam-Vigh H; Suppli MP; Gasbjerg LS; Vilsbøll T; Knop FK
Peptides; 2024 Jul; 177():171227. PubMed ID: 38657907
[TBL] [Abstract][Full Text] [Related]
4. LEAP2 changes with body mass and food intake in humans and mice.
Mani BK; Puzziferri N; He Z; Rodriguez JA; Osborne-Lawrence S; Metzger NP; Chhina N; Gaylinn B; Thorner MO; Thomas EL; Bell JD; Williams KW; Goldstone AP; Zigman JM
J Clin Invest; 2019 Sep; 129(9):3909-3923. PubMed ID: 31424424
[TBL] [Abstract][Full Text] [Related]
5. Ghrelin and LEAP-2: Rivals in Energy Metabolism.
Al-Massadi O; Müller T; Tschöp M; Diéguez C; Nogueiras R
Trends Pharmacol Sci; 2018 Aug; 39(8):685-694. PubMed ID: 30037389
[TBL] [Abstract][Full Text] [Related]
6. Growth hormone secretagogue receptor signalling affects high-fat intake independently of plasma levels of ghrelin and LEAP2, in a 4-day binge eating model.
Cornejo MP; Castrogiovanni D; Schiöth HB; Reynaldo M; Marie J; Fehrentz JA; Perello M
J Neuroendocrinol; 2019 Oct; 31(10):e12785. PubMed ID: 31469195
[TBL] [Abstract][Full Text] [Related]
7. Ghrelin receptor signaling is not required for glucocorticoid-induced obesity in female mice.
Silver Z; Abbott-Tate S; Hyland L; Sherratt F; Woodside B; Abizaid A
J Endocrinol; 2021 Jun; 250(2):37-48. PubMed ID: 34060474
[TBL] [Abstract][Full Text] [Related]
8. Liver-expressed antimicrobial peptide 2 functions independently of growth hormone secretagogue receptor in calorie-restricted mice.
Islam MN; Zhang W; Sakai K; Nakazato Y; Tanida R; Sakoda H; Takei T; Takao T; Nakazato M
Peptides; 2022 May; 151():170763. PubMed ID: 35151767
[TBL] [Abstract][Full Text] [Related]
9. Liver-Expressed Antimicrobial Peptide 2 antagonizes the insulinostatic effect of ghrelin in rat isolated pancreatic islets.
Bayle M; Péraldi-Roux S; Gautheron G; Cros G; Oiry C; Neasta J
Fundam Clin Pharmacol; 2022 Apr; 36(2):375-377. PubMed ID: 34449915
[TBL] [Abstract][Full Text] [Related]
10. LEAP2 reduces postprandial glucose excursions and
Hagemann CA; Jensen MS; Holm S; Gasbjerg LS; Byberg S; Skov-Jeppesen K; Hartmann B; Holst JJ; Dela F; Vilsbøll T; Christensen MB; Holst B; Knop FK
Cell Rep Med; 2022 Apr; 3(4):100582. PubMed ID: 35492241
[TBL] [Abstract][Full Text] [Related]
11. Enhanced responsiveness of Ghsr Q343X rats to ghrelin results in enhanced adiposity without increased appetite.
Chebani Y; Marion C; Zizzari P; Chettab K; Pastor M; Korostelev M; Geny D; Epelbaum J; Tolle V; Morisset-Lopez S; Pantel J
Sci Signal; 2016 Apr; 9(424):ra39. PubMed ID: 27095593
[TBL] [Abstract][Full Text] [Related]
12. Development of a novel fluorescent ligand of growth hormone secretagogue receptor based on the N-Terminal Leap2 region.
Barrile F; M'Kadmi C; De Francesco PN; Cabral A; García Romero G; Mustafá ER; Cantel S; Damian M; Mary S; Denoyelle S; Banères JL; Marie J; Raingo J; Fehrentz JA; Perelló M
Mol Cell Endocrinol; 2019 Dec; 498():110573. PubMed ID: 31499133
[TBL] [Abstract][Full Text] [Related]
13. Ghrelin, obesity and diabetes.
Wiedmer P; Nogueiras R; Broglio F; D'Alessio D; Tschöp MH
Nat Clin Pract Endocrinol Metab; 2007 Oct; 3(10):705-12. PubMed ID: 17893689
[TBL] [Abstract][Full Text] [Related]
14. Identifying the binding mechanism of LEAP2 to receptor GHSR1a.
Wang JH; Li HZ; Shao XX; Nie WH; Liu YL; Xu ZG; Guo ZY
FEBS J; 2019 Apr; 286(7):1332-1345. PubMed ID: 30666806
[TBL] [Abstract][Full Text] [Related]
15. Ghrelin's Relationship to Blood Glucose.
Mani BK; Shankar K; Zigman JM
Endocrinology; 2019 May; 160(5):1247-1261. PubMed ID: 30874792
[TBL] [Abstract][Full Text] [Related]
16. LEAP-2 Counteracts Ghrelin-Induced Food Intake in a Nutrient, Growth Hormone and Age Independent Manner.
Lugilde J; Casado S; Beiroa D; Cuñarro J; Garcia-Lavandeira M; Álvarez CV; Nogueiras R; Diéguez C; Tovar S
Cells; 2022 Jan; 11(3):. PubMed ID: 35159134
[TBL] [Abstract][Full Text] [Related]
17. LEAP2 Is an Endogenous Antagonist of the Ghrelin Receptor.
Ge X; Yang H; Bednarek MA; Galon-Tilleman H; Chen P; Chen M; Lichtman JS; Wang Y; Dalmas O; Yin Y; Tian H; Jermutus L; Grimsby J; Rondinone CM; Konkar A; Kaplan DD
Cell Metab; 2018 Feb; 27(2):461-469.e6. PubMed ID: 29233536
[TBL] [Abstract][Full Text] [Related]
18. Ghrelin acylation and metabolic control.
Al Massadi O; Tschöp MH; Tong J
Peptides; 2011 Nov; 32(11):2301-8. PubMed ID: 21893140
[TBL] [Abstract][Full Text] [Related]
19. Mice lacking ghrelin receptors resist the development of diet-induced obesity.
Zigman JM; Nakano Y; Coppari R; Balthasar N; Marcus JN; Lee CE; Jones JE; Deysher AE; Waxman AR; White RD; Williams TD; Lachey JL; Seeley RJ; Lowell BB; Elmquist JK
J Clin Invest; 2005 Dec; 115(12):3564-72. PubMed ID: 16322794
[TBL] [Abstract][Full Text] [Related]
20. Ghrelin Receptor Signaling Is Not Required for Glucocorticoid-Induced Obesity in Male Mice.
Hay RE; Edwards A; Klein M; Hyland L; MacDonald D; Karatsoreos I; Hill MN; Abizaid A
Endocrinology; 2020 Mar; 161(3):. PubMed ID: 31748785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
